A
Alexander Swarbrick
Researcher at Garvan Institute of Medical Research
Publications - 130
Citations - 5352
Alexander Swarbrick is an academic researcher from Garvan Institute of Medical Research. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 35, co-authored 110 publications receiving 3662 citations. Previous affiliations of Alexander Swarbrick include University of New South Wales & University of California, San Francisco.
Papers
More filters
Journal ArticleDOI
A single-cell and spatially resolved atlas of human breast cancers.
Sunny Z. Wu,Sunny Z. Wu,Ghamdan Al-Eryani,Ghamdan Al-Eryani,Daniel L. Roden,Daniel L. Roden,Simon Junankar,Simon Junankar,Kate Harvey,Alma Andersson,Aatish Thennavan,Chenfei Wang,James R. Torpy,James R. Torpy,Nenad Bartonicek,Nenad Bartonicek,Taopeng Wang,Taopeng Wang,Ludvig Larsson,Dominik C. Kaczorowski,Neil I. Weisenfeld,Cedric Uytingco,Jennifer Chew,Zachary Bent,Chia-Ling Chan,Vikkitharan Gnanasambandapillai,Charles-Antoine Dutertre,Charles-Antoine Dutertre,Laurence Gluch,Mun N. Hui,Jane Beith,Andrew Parker,Andrew Parker,Elizabeth Robbins,Davendra Segara,Caroline Cooper,Caroline Cooper,Cindy Mak,Belinda Chan,Sanjay Warrier,Florent Ginhoux,Florent Ginhoux,Florent Ginhoux,Ewan K.A. Millar,Ewan K.A. Millar,Ewan K.A. Millar,Joseph E. Powell,Joseph E. Powell,Stephen R. Williams,X. Shirley Liu,Sandra A O'Toole,Elgene Lim,Elgene Lim,Elgene Lim,Joakim Lundeberg,Charles M. Perou,Alexander Swarbrick,Alexander Swarbrick +57 more
TL;DR: In this paper, a single-cell and spatially resolved transcriptomics analysis of human breast cancers is presented, which reveals recurrent neoplastic cell heterogeneity and heterotypic interactions play central roles in disease progression.
Journal ArticleDOI
Targeting stromal remodeling and cancer stem cell plasticity overcomes chemoresistance in triple negative breast cancer
Aurélie Cazet,Aurélie Cazet,Mun N. Hui,Benjamin Elsworth,Sunny Z. Wu,Sunny Z. Wu,Daniel L. Roden,Daniel L. Roden,Chia Ling Chan,Joanna N. Skhinas,Raphael Collot,Jessica Yang,Kate Harvey,M. Zahied Johan,M. Zahied Johan,Caroline Cooper,Radhika Nair,David Herrmann,David Herrmann,Andrea McFarland,Niantao Deng,Niantao Deng,Manuel Ruiz-Borrego,Federico Rojo,Jose Manuel Trigo,Susana Bezares,Rosalía Caballero,Elgene Lim,Paul Timpson,Paul Timpson,Sandra A O'Toole,Sandra A O'Toole,D. Neil Watkins,Thomas R. Cox,Thomas R. Cox,Michael S. Samuel,Michael S. Samuel,Miguel Martin,Alexander Swarbrick,Alexander Swarbrick +39 more
TL;DR: It is demonstrated that cancer cell-derived Hedgehog ligand triggers stromal remodeling that in turn induces a cancer-stem-cell like, drug-resistant phenotype of nearby cancer cells while treatment with smoothened inhibitors reverses these phenotypes.
Journal ArticleDOI
miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastoma
Alexander Swarbrick,Alexander Swarbrick,Susan L. Woods,Susan L. Woods,Alex D. Shaw,Alex D. Shaw,Alex D. Shaw,Asha Balakrishnan,Yuwei Phua,Yuwei Phua,Akira Nguyen,Yvan Chanthery,Lionel Lim,Lesley J. Ashton,Robert L. Judson,Noelle E. Huskey,Robert Blelloch,Michelle Haber,Murray D. Norris,Peter Lengyel,Christopher S. Hackett,Thomas Preiss,Thomas Preiss,Albert Chetcuti,Christopher S. Sullivan,Eric G. Marcusson,William A. Weiss,Noelle D. L'Etoile,Andrei Goga +28 more
TL;DR: A new mechanism of p53 regulation in cancer and stem cells is demonstrated and a potential therapeutic target for neuroblastoma is uncovered.
Journal ArticleDOI
Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome.
Rhiannon K. Beckers,Christina I. Selinger,Ricardo E. Vilain,Ricardo E. Vilain,Jason Madore,James S. Wilmott,Kate Harvey,Kate Harvey,Anne Holliday,Caroline L. Cooper,Caroline L. Cooper,Elizabeth Robbins,David Gillett,Catherine Kennedy,Laurence Gluch,Laurence Gluch,Hugh Carmalt,Hugh Carmalt,Cindy Mak,Sanjay Warrier,Sanjay Warrier,Harriet E. Gee,Charles Chan,Charles Chan,Anna McLean,Emily Walker,Catriona M. McNeil,Jane Beith,Alexander Swarbrick,Alexander Swarbrick,Richard A. Scolyer,Richard A. Scolyer,Sandra A O'Toole +32 more
TL;DR: Clinical trials targeting programmed death 1/programmed death ligand 1 (PD1/PDL1) in melanoma and non‐small‐cell lung cancer have reported high response rates, and tumoral PDL1 expression has been suggested as a potential biomarker to enrich for patient response to these treatments.
Journal ArticleDOI
Stromal cell diversity associated with immune evasion in human triple-negative breast cancer.
Sunny Z. Wu,Sunny Z. Wu,Daniel L. Roden,Daniel L. Roden,Chenfei Wang,Holly Holliday,Holly Holliday,Kate Harvey,Aurélie Cazet,Aurélie Cazet,Kendelle J. Murphy,Kendelle J. Murphy,Brooke A. Pereira,Brooke A. Pereira,Ghamdan Al-Eryani,Ghamdan Al-Eryani,Nenad Bartonicek,Nenad Bartonicek,Rui Hou,James R. Torpy,James R. Torpy,Simon Junankar,Simon Junankar,Chia Ling Chan,Chuan En Lam,Mun N. Hui,Laurence Gluch,Jane Beith,Andrew Parker,Elizabeth Robbins,Davendra Segara,Cindy Mak,Caroline Cooper,Caroline Cooper,Sanjay Warrier,Alistair R. R. Forrest,Joseph E. Powell,Joseph E. Powell,Sandra A O'Toole,Sandra A O'Toole,Thomas R. Cox,Thomas R. Cox,Paul Timpson,Paul Timpson,Elgene Lim,Elgene Lim,Elgene Lim,X. Shirley Liu,Alexander Swarbrick,Alexander Swarbrick +49 more
TL;DR: Investigation of gene signatures from inflammatory‐CAFs and differentiated‐PVL cells in independent TNBC patient cohorts revealed strong associations with cytotoxic T‐cell dysfunction and exclusion, respectively, presenting promising candidates for new therapeutic strategies in the treatment of TNBCs.